About Jasper Therapeutics
Jasper Therapeutics is a company based in Redwood City (United States) founded in 1999 by Judith Shizuru and Susan Prohaska. Jasper Therapeutics has raised $216.1 million across 4 funding rounds from investors including Roche, ARE and Citadel. Jasper Therapeutics operates in a competitive market with competitors including BridgeBio, Moderna, Forge Biologics, Spark Therapeutics and Mereo BioPharma, among others.
- Headquarter Redwood City, United States
- Founders Judith Shizuru, Susan Prohaska
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$216.1 M (USD)
in 4 rounds
-
Latest Funding Round
$132 M (USD), Series B
Jul 21, 2026
-
Investors
Roche
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Jasper Therapeutics
Jasper Therapeutics has successfully raised a total of $216.1M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $132 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Jasper Therapeutics
Jasper Therapeutics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, ARE and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare companies are funded by Qiming, a venture capital firm.
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
Locked | Locked | Locked |
Investor details for Jasper Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Jasper Therapeutics
Investment portfolio details for Jasper Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Jasper Therapeutics
Detailed financials for Jasper Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Jasper Therapeutics Comparisons
Peer comparison for Jasper Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Jasper Therapeutics
Jasper Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Moderna, Forge Biologics, Spark Therapeutics and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
Detailed competitors of Jasper Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Jasper Therapeutics
Complete news archive for Jasper Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jasper Therapeutics
Jasper Therapeutics was founded in 1999 and raised its 1st funding round 20 years after it was founded.
Jasper Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Ronald Martell is the current CEO of Jasper Therapeutics.
Jasper Therapeutics is a funded company, having raised a total of $216.1M across 4 funding rounds to date.
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells. It offers Briquilimab a targeted anti c-Kit monoclonal antibody to deplete mast cells and diseased stem cells for chronic urticaria and lower to intermediate risk myelodysplastic syndromes.
Jasper Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Jasper Therapeutics has 5 investors. Key investors include Roche, ARE, Citadel, Abingworth, and Qiming.